GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » Piotroski F-Score

BioDelivery Sciences International (BioDelivery Sciences International) Piotroski F-Score : 6 (As of Apr. 25, 2024)


View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioDelivery Sciences International has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for BioDelivery Sciences International's Piotroski F-Score or its related term are showing as below:

BDSI' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of BioDelivery Sciences International was 8. The lowest was 1. And the median was 4.


BioDelivery Sciences International Piotroski F-Score Historical Data

The historical data trend for BioDelivery Sciences International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Piotroski F-Score Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 6.00 6.00 6.00

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 8.00 8.00 7.00 6.00

Competitive Comparison of BioDelivery Sciences International's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec21) TTM:Last Year (Dec20) TTM:
Net Income was 5.237 + 9.064 + 6.669 + 63.89 = $84.9 Mil.
Cash Flow from Operations was 11.097 + 9.23 + 6.962 + 13.748 = $41.0 Mil.
Revenue was 41.02 + 41.439 + 41.092 + 43.154 = $166.7 Mil.
Gross Profit was 35.199 + 37.155 + 34.727 + 36.251 = $143.3 Mil.
Average Total Assets from the begining of this year (Dec20)
to the end of this year (Dec21) was
(239.894 + 242.13 + 250.327 + 256.07 + 324.596) / 5 = $262.6034 Mil.
Total Assets at the begining of this year (Dec20) was $239.9 Mil.
Long-Term Debt & Capital Lease Obligation was $54.2 Mil.
Total Current Assets was $202.1 Mil.
Total Current Liabilities was $82.4 Mil.
Net Income was 4.966 + 1.165 + 9.383 + 10.196 = $25.7 Mil.

Revenue was 38.278 + 36.582 + 39.443 + 42.167 = $156.5 Mil.
Gross Profit was 32.718 + 31.147 + 34.067 + 33.873 = $131.8 Mil.
Average Total Assets from the begining of last year (Dec19)
to the end of last year (Dec20) was
(182.905 + 196.616 + 220.073 + 227.957 + 239.894) / 5 = $213.489 Mil.
Total Assets at the begining of last year (Dec19) was $182.9 Mil.
Long-Term Debt & Capital Lease Obligation was $78.5 Mil.
Total Current Assets was $182.4 Mil.
Total Current Liabilities was $53.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioDelivery Sciences International's current Net Income (TTM) was 84.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BioDelivery Sciences International's current Cash Flow from Operations (TTM) was 41.0. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec20)
=84.86/239.894
=0.35373957

ROA (Last Year)=Net Income/Total Assets (Dec19)
=25.71/182.905
=0.14056477

BioDelivery Sciences International's return on assets of this year was 0.35373957. BioDelivery Sciences International's return on assets of last year was 0.14056477. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

BioDelivery Sciences International's current Net Income (TTM) was 84.9. BioDelivery Sciences International's current Cash Flow from Operations (TTM) was 41.0. ==> 41.0 <= 84.9 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=54.177/262.6034
=0.20630731

Gearing (Last Year: Dec20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Dec20
=78.452/213.489
=0.36747561

BioDelivery Sciences International's gearing of this year was 0.20630731. BioDelivery Sciences International's gearing of last year was 0.36747561. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec21)=Total Current Assets/Total Current Liabilities
=202.065/82.378
=2.45290005

Current Ratio (Last Year: Dec20)=Total Current Assets/Total Current Liabilities
=182.385/52.995
=3.44155109

BioDelivery Sciences International's current ratio of this year was 2.45290005. BioDelivery Sciences International's current ratio of last year was 3.44155109. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

BioDelivery Sciences International's number of shares in issue this year was 102.75. BioDelivery Sciences International's number of shares in issue last year was 105.741. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=143.332/166.705
=0.85979425

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=131.805/156.47
=0.84236595

BioDelivery Sciences International's gross margin of this year was 0.85979425. BioDelivery Sciences International's gross margin of last year was 0.84236595. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec20)
=166.705/239.894
=0.69491109

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec19)
=156.47/182.905
=0.85547142

BioDelivery Sciences International's asset turnover of this year was 0.69491109. BioDelivery Sciences International's asset turnover of last year was 0.85547142. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BioDelivery Sciences International has an F-score of 6 indicating the company's financial situation is typical for a stable company.

BioDelivery Sciences International  (NAS:BDSI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


BioDelivery Sciences International Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.
Executives
James Vollins officer: See Remarks C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd director C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho officer: See Remarks 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey director, officer: Chief Executive Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc director 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha officer: See Remarks 1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr director BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier director, officer: Chief Executive Officer C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith officer: Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612

BioDelivery Sciences International (BioDelivery Sciences International) Headlines

From GuruFocus